The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors.
L. S. Rosen
No relevant relationships to disclose
M. S. Gordon
Consultant or Advisory Role - Genentech
Research Funding - Genentech
S. Bai
Employment or Leadership Position - Genentech
Stock Ownership - Roche
P. Hegde
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. Fredrickson
Employment or Leadership Position - Genentech
Stock Ownership - Roche
D. S. Chen
Employment or Leadership Position - Genentech
Stock Ownership - Roche
I. Chang
Employment or Leadership Position - Genentech
Stock Ownership - Roche
R. P. Funke
Employment or Leadership Position - Genentech
Stock Ownership - Roche
G. S. Chandler
Employment or Leadership Position - Genentech
Stock Ownership - Roche
L. Naumovski
Employment or Leadership Position - Genentech
Stock Ownership - Roche
P. N. Munster
No relevant relationships to disclose